JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Molderings, G. J.
Right arrow Articles by Göthert, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molderings, G. J.
Right arrow Articles by Göthert, M.

Vol. 285, Issue 1, 170-177, April 1998

Characterization of I2 Imidazoline and sigma  Binding Sites in the Rat and Human Stomach

Gerhard J. Molderings, Kurt Donecker, Maria Burian, W. Alexander Simon, Detlev W. Schröder and Manfred Göthert

Institute of Pharmacology and Toxicology (G.J.M., K.D., M.B., M.G.), University of Bonn, Bonn, Germany, Byk Gulden Lomberg GmbH (W.A.S.), Konstanz, Germany and Evangelisches Krankenhaus (D.W.S.), Bonn, Germany

Radioligand binding experiments were carried out to identify and characterize nonadrenoceptor [3H]idazoxan binding sites and [3H](1,2-di-(2-tolyl)guanidine) binding sites in the rat and human stomach. Furthermore, we examined two selected aspects of their potential functional significance. Binding of [3H]idazoxan (Kd = 11.1 nM and 12.4 nM, respectively) and [3H]DTG (Kd = 932 nM and 242 nM, respectively) to cell membranes from rat and human stomach was rapid, reversible, specific and saturable. In rat stomach, binding of the radioligands was inhibited by imidazolines and by nonimidazoline sigma -site ligands, respectively, at different rank orders of affinity, which suggests the existence of I2-imidazoline binding sites as well as sigma 2-sites. In two functional models, the direct effects of I2-site ligands and sigma 2-site ligands on gastric smooth muscle and glands were investigated. (1) Cirazoline, clonidine and 4-chloro-2-(2-imidazolin-2-ylamino)-isoindoline (BDF 6143) failed to contract the longitudinal muscle of the rat stomach fundus; BDF 6143 also failed to induce relaxation of this preparation when it was precontracted with 30 mM KCl. (2) Clonidine, idazoxan, BDF 6143, 1,2-di-(2-tolyl)guanidine, agmatine and (R)-3-(3-hydroxyphenyl)-N-propylpiperidine up to 100 µM did not induce acid secretion from rabbit isolated gastric glands. Our data provide evidence that the rat stomach is endowed with sigma 2 sites and I2 binding sites in addition to the previously identified non-I1/non-I2 [3H]clonidine binding sites. Our experiments also offer basic evidence of the existence of I2 and sigma  binding sites in the human stomach. Neither the I2 and [3H]clonidine binding sites nor the sigma  sites in rat stomach are directly related to a postsynaptic effect on gastric smooth muscle or to acid release from isolated gastric glands.


0022-3565/98/2851-0170$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.